Shopping Cart
Expert article · Evidence review · Updated 01 September 2026
PRP in Alzheimer’s, Parkinson’s and ALS: What the Research Really Shows in 2026
Platelets and the factors they release have been investigated for years as possible building blocks for new approaches in neuromedicine. The key point is that the literature does not deal only with conventional platelet-rich plasma. PRGF, platelet lysate, secretome and platelet-derived extracellular vesicles are biologically and technologically different preparations.
Short answer: Based on the research available up to 1 September 2026, there is no established PRP treatment for Alzheimer’s disease, Parkinson’s disease or ALS. There are interesting cell and animal data. In Alzheimer’s disease, the animal findings are even contradictory. For Parkinson’s disease, one small human publication evaluated a combination of PRP and experimental cell therapy, so it cannot determine the isolated effect of PRP.
Alzheimer’sParkinson’sALSPRP ≠ Platelet lysatepreclinical ≠ clinical
Context: This article summarizes research data and is not a treatment recommendation. Experimental intranasal, intrathecal or intracerebral routes are mentioned only to describe published studies, not as instructions or recommendations.
Why are platelets being studied in neuromedicine at all?
Platelets are more than components of haemostasis. They store and release numerous biologically active molecules. A recent review in Trends in Molecular Medicine describes trophic factors, cytokines, chemokines, lipids, antioxidants, non-coding RNAs and extracellular vesicles among the components of platelet-based preparations. Neuroprotective, inflammation-modulating and anti-ferroptotic effects have been investigated in models of neurodegeneration, trauma and ageing.[1]
That provides a plausible research basis, but it is not yet evidence of clinical efficacy. There is also a countervailing aspect: altered platelet function has been described in neurodegenerative diseases. Depending on context, platelets may therefore be relevant both as a biological resource and as part of disease-related processes.[2]
BiologyA multifactorial signal profileNo single growth factor explains the observed effects.
ProductionProcessing changes the preparationActivation, heat treatment, filtration and fractionation can alter composition and biological potency.[1]
TranslationAn animal model is not a therapyImprovement in a mouse or rat model does not establish clinical benefit in humans.
The most important point: PRP, PRGF and platelet lysate are not the same
Much of the apparent “PRP evidence” arises when different blood- and platelet-derived products are grouped under one label. A meaningful assessment requires these preparations to be separated.
| Term | What does it mean? | Why the distinction matters |
|---|---|---|
| PRP | Platelet-rich plasma: a platelet-enriched plasma fraction, usually autologous. | Its composition depends strongly on preparation method, cellular content, activation and the source blood. |
| PRGF | Plasma Rich in Growth Factors; in the studies discussed here, mainly PRGF-Endoret. | A defined preparation and activation concept; findings cannot automatically be transferred to every PRP preparation. |
| Platelet lysate | Platelet components released by lysis; in neurological research sometimes heated, purified, filtered or fractionated. | The final preparation may contain virtually no intact platelets and differs substantially from routine PRP. |
| Secretome / supernatant | Released soluble factors and, depending on the process, vesicles after activation or processing. | Its composition depends on the manufacturing process. |
| Platelet-derived EVs | Extracellular vesicles derived from platelets. | A separate research field with its own manufacturing, characterisation and quality questions. |
The 2026 neuromedicine review therefore does not treat this as “one PRP”, but as a platform of different platelet-derived biotherapies. For clinical translation it calls for standardised, characterised and GMP-compatible preparations.[1]
Evidence matrix: where does the research really stand?
| Disease / approach | Cell / mechanistic data | Animal data | Human data | Assessment 01 Sep 2026 |
|---|---|---|---|---|
| Alzheimer’s – PRGF | available | contradictory | no robust efficacy evidence identified | preclinical, not established |
| Parkinson’s – PRP/PRGF | available | several positive models | very limited combination signal | experimental |
| Parkinson’s – platelet lysate | positive in models | positive models | no robust efficacy study identified | preclinical |
| ALS – platelet lysate | positive cell models | positive SOD1 mouse model | no robust efficacy study identified | preclinical |
| Secretome / EVs | broad mechanistic research | several neurological models | no disease-specific efficacy established | translational research |
Interactive evidence map
The bars do not show effect size. They indicate how far the research pathway has progressed by 1 September 2026. Open a disease to compare the stages.
Alzheimer’spreclinical · mixed
For Alzheimer’s disease, positive APP/PS1 models are countered by a 5xFAD study reporting unfavourable effects. No robust clinical efficacy evidence for PRP or PRGF was identified.
Parkinson’spreclinical · stronger
For Parkinson’s disease, several animal models are positive. The small human publication, however, evaluates a complex combination of PRP and experimental cell therapy and does not isolate the PRP effect.
ALSpreclinical
For ALS, the most interesting findings concern specially processed platelet lysate. No robust human efficacy evidence for conventional PRP was identified.
How to read this: research maturity, not treatment effect or probability of success.
Alzheimer’s disease: positive APP/PS1 data – but an important counter-study
The best-known studies come from animal models using intranasally administered PRGF-Endoret. In 2013, Anitua and colleagues reported more markers of hippocampal neurogenesis and fewer degenerating neurons after chronic treatment in APP/PS1 mice.[3] A further APP/PS1 study followed in 2014: after PRGF-Endoret, Aβ deposition and tau phosphorylation were among the measures reported as reduced, while synaptic markers and behavioural parameters were more favourable.[4]
1
Cell models
Cell models
2
Animal models
mixed
Animal models
mixed
3
Early human studies
Early human studies
4
Controlled human studies
Controlled human studies
5
Established PRP therapy
Established PRP therapy
The counter-study matters: In 2019, Duong and colleagues studied PRGF in a different Alzheimer model, 5xFAD mice. Although a cell model initially showed favourable effects, in vivo PRGF impaired blood-brain barrier integrity and was associated with greater amyloid deposition, apoptosis and neuroinflammation.[5] The preclinical Alzheimer findings are therefore not consistent.
Up to the review cut-off, no controlled human study was identified that demonstrates clinical efficacy of PRP or PRGF in Alzheimer’s disease. The intranasal “pilot study” in Alzheimer patients previously claimed in this blog is therefore explicitly not carried over.
The therapeutic context has also changed. Lecanemab (Leqembi) and donanemab (Kisunla) are now authorised in the EU as anti-amyloid therapies for clearly defined groups with early Alzheimer’s disease. Both can slow disease progression in suitable patients, but they carry relevant risks and require strict patient selection and monitoring.[14][15]
View the Alzheimer studies in more detail
2013, APP/PS1 mouse model: intranasal PRGF-Endoret; more BrdU-, DCX- and NeuN-positive cells and fewer Fluoro-Jade-B-positive degenerating neurons.[3]
2014, APP/PS1 mouse model: less Aβ deposition and tau phosphorylation, lower astrocyte reactivity, protection of synaptic proteins and more favourable behavioural parameters.[4]
2019, 5xFAD mouse model: unfavourable in-vivo effects on the blood-brain barrier and amyloid pathology despite positive effects in the cell model.[5]
Parkinson’s disease: stronger preclinical signals, but still no robust clinical evidence
The preclinical evidence base is broader for Parkinson’s disease. In 2015, intranasal PRGF-Endoret in an MPTP mouse model was associated with fewer neuroinflammatory signals, better preservation of dopaminergic neurons and better motor performance.[6]
In 2017, a specially developed platelet-pellet lysate was studied. It was produced from platelet concentrates, lysed by freeze-thaw cycles, heated and processed to markedly reduce plasma and fibrinogen content as well as procoagulant activity. This product showed neuroprotective effects in cell and MPTP mouse models.[7] This is scientifically interesting, but it is not evidence for conventional autologous PRP.
A 2025 study then examined specially prepared human platelet lysate in rotenone-based cell and rat models. Reported findings included more favourable oxidative-stress markers, lower glial activation and better motor test results.[8]
A 2026 paper in Experimental Neurology did investigate PRP itself: 40 male rats were divided into five groups. After rotenone-induced Parkinson-like pathology, animals received interventions including intravenous PRP, L-DOPA or the combination. PRP alone favourably affected several oxidative, inflammatory and motor endpoints; the PRP/L-DOPA combination performed best on several measures.[9] Again, this is a chemically induced animal model, not evidence of treatment efficacy in humans.
What about the human study published in 2025?
It deserves mention, but not overinterpretation. The quasi-experimental study compared 25 patients receiving standard therapy with 25 patients who additionally received a combination of PRP and PBD-VSEL cell therapy. PRP was administered at four acupuncture points; cell therapy followed, and additional intradiscal interventions were described in individual patients.[10]
After one year, several between-group comparisons were more favourable. In the repeated-measures analysis, however, the key time×group interaction for the UPDRS motor score was not significant (p=0.550), while it was significant for the PDQ-39 quality-of-life score.[10] More importantly, the design cannot show what share of any possible effect came from PRP, the cell therapy, accompanying interventions or other factors.
Additional uncertainty: The associated ClinicalTrials.gov entry NCT06142981 lists 30 participants aged 30–50 years. The publication describes 50 participants with an inclusion age of 50–70 years. No results are posted in the registry.[11] This does not make the study worthless, but it further limits its reliability as evidence of efficacy.
B1 assessment – Parkinson’s: A more consistent preclinical signal is emerging across several platelet-based preparations. The available human literature is not sufficient to establish clinical efficacy of PRP in Parkinson’s disease.
ALS: the most interesting data concern specially processed platelet lysates
In ALS, the gap between what is studied in the laboratory and conventional PRP is particularly large. In 2017, human platelet lysate protected against several forms of cell death and oxidative stress in cellular models of Parkinson’s disease and ALS. Akt and MEK signalling pathways were among the mechanisms investigated.[12]
A 2022 Biomaterials paper went further: heat-treated human platelet lysate and size-fractionated components were tested in motor neurons and in the SOD1-G86R mouse model. Whole lysate was administered intracerebroventricularly; a fraction <3 kDa was given intranasally. Both approaches prolonged lifespan in this mouse model.[13]
This is a noteworthy preclinical signal, but it concerns a technologically processed platelet-lysate biomaterial, not the usual autologous PRP fraction produced by routine centrifugation. No controlled human study was identified that establishes PRP or platelet lysate as an effective treatment for ALS.
It would also now be too broad to say that no disease-specific therapy exists for ALS at all. Tofersen (Qalsody) is authorised in the EU for adults with SOD1-mutated ALS. This genetic form affects only a small proportion of people with ALS; the EMA authorisation was granted under exceptional circumstances.[16]
Why good animal data cannot simply be translated into a PRP therapy
1 · ProductNot the same substancePRP, PRGF, heat-treated HPL, fractionated lysate and EVs have different compositions.
2 · SourceHealthy donor ≠ patientMany platelet-lysate models use pooled platelets from healthy donors. In neurodegeneration, platelet biology itself may be altered.[1][2]
3 · ModelRotenone/MPTP ≠ idiopathic Parkinson’sAnimal models reproduce only selected aspects of a complex human disease.
4 · Target organThe CNS is difficult to reachDistribution, dose, biological barriers and safety requirements differ fundamentally from local PRP applications.
5 · ManufacturingStandardisation is missingCurrent research is therefore moving towards defined, characterised and GMP-compatible platelet-derived products.[1]
6 · EndpointA biomarker is not automatically patient benefitLower cytokine levels or better histology in an animal model do not replace clinical outcomes in humans.
What can reasonably be said in 2026?
Research on platelets and neuromedicine is real and continues to develop. Platelet lysates, secretome fractions and platelet-derived extracellular vesicles in particular are being investigated as possible multifactorial, cell-free biotherapies. A 2026 review presents them as a rational platform for future neuromedicine while highlighting major unresolved issues around manufacturing, standardisation, biomarkers, dosing and clinical translation.[1]
For the three diseases discussed here, the picture is much more differentiated than the phrase “PRP for Alzheimer’s and Parkinson’s” suggests:
Alzheimer’s: preclinically interesting, but animal data are contradictory and there is no robust clinical PRP efficacy evidence. Parkinson’s: several positive animal models; one small human study evaluates only a complex combination therapy and does not establish a PRP effect. ALS: relevant preclinical data exist for specially processed platelet lysate, but no robust human efficacy evidence has been established.
The more useful research question is therefore not simply “Can PRP be used against neurodegeneration?” It is: Which precisely defined platelet-derived fraction affects which disease mechanism, at what dose and through which safe route of administration – and can that effect be reproduced in humans?
Further reading on prpmed.de
FAQ: PRP and neurodegenerative diseases
Can PRP treat Alzheimer’s disease?
Are there human studies of PRP in Parkinson’s disease?
A quasi-experimental human study was published in 2025. It did not test PRP in isolation, but a combination of PRP, PBD-VSEL cell therapy and standard therapy. It therefore cannot establish an independent effect of PRP.[10]
Is platelet lysate the same as PRP?
Why are the animal studies still relevant?
They help identify mechanisms, safety questions, distribution and candidates for further research. They do not demonstrate that an intervention is effective or clinically appropriate in humans.
What is currently the most interesting research direction?
Research is shifting from nonspecific “PRP” towards standardised platelet-derived products: platelet lysates, secretome fractions, extracellular vesicles and defined subfractions. That standardisation is central to later clinical testing.[1]
Selected primary sources and current context
- Chou ML, Blum D, Cognasse F, et al. Platelet-derived and platelet secretome biotherapies for precision neuromedicine. Trends Mol Med. 2026. DOI: 10.1016/j.molmed.2026.02.006. PMID 41904071.
- Leiter O, Walker TL. Platelets in Neurodegenerative Conditions—Friend or Foe? Front Immunol. 2020;11:747. DOI: 10.3389/fimmu.2020.00747. PMID 32431701.
- Anitua E, et al. Intranasal delivery of plasma and platelet growth factors using PRGF-Endoret system enhances neurogenesis in a mouse model of Alzheimer's disease. PLoS One. 2013;8:e73118. DOI: 10.1371/journal.pone.0073118. PMID 24069173.
- Anitua E, et al. Plasma rich in growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves cognitive functions in an Alzheimer's disease mouse model. Neurobiol Aging. 2014;35(7):1582–1595. DOI: 10.1016/j.neurobiolaging.2014.01.009. PMID 24524966.
- Duong QV, et al. Plasma Rich in Growth Factors (PRGF) Disrupt the Blood-Brain Barrier Integrity and Elevate Amyloid Pathology in the Brains of 5XFAD Mice. Int J Mol Sci. 2019;20(6):1489. DOI: 10.3390/ijms20061489. PMID 30934587.
- Anitua E, et al. Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-κB-dependent inflammation process in a mouse model of Parkinson's disease. J Control Release. 2015;203:170–180. DOI: 10.1016/j.jconrel.2015.02.030. PMID 25702964.
- Chou ML, et al. Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's disease. Biomaterials. 2017;142:77–89. DOI: 10.1016/j.biomaterials.2017.07.018. PMID 28728000.
- Beura SK, et al. Neuroprotective Potential of Human Platelet Lysate in Parkinson's Disease: Insights Into Oxidative Stress, Mitochondrial Dysfunction, Cell Death, and Reactive Gliosis in Experimental Models. Biotechnol J. 2025;20(7):e70064. DOI: 10.1002/biot.70064. PMID 40611714.
- Elghareeb MM, et al. Platelet-rich plasma intervention as a therapeutic agent versus L-DOPA in Parkinson's model induced by rotenone in male albino rats. Exp Neurol. 2026;396:115545. DOI: 10.1016/j.expneurol.2025.115545. PMID 41213495.
- Anwar S, Hassan A, Waseem H, et al. Effectiveness of platelet-rich plasma and peripheral blood-derived very small embryonic-like stem cells in Parkinson’s disease management. Biomedical Research and Therapy. 2025;12(3):7236–7245. DOI: 10.15419/bmrat.v12i3.966.
- ClinicalTrials.gov. PRP and PBD-VSEL Stem Cell Therapy for Parkinson's Disease. NCT06142981. ClinicalTrials.gov, accessed 01.09.2026.
- Gouel F, et al. The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways. J Tissue Eng Regen Med. 2017;11(11):3236–3240. DOI: 10.1002/term.2222. PMID 27943621.
- Gouel F, et al. Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis. Biomaterials. 2022;280:121311. DOI: 10.1016/j.biomaterials.2021.121311. PMID 34952382.
- European Medicines Agency. Leqembi (lecanemab) – EPAR. EU authorisation 15.04.2025. EMA.
- European Medicines Agency. Kisunla (donanemab) – EPAR. EU authorisation 24.09.2025. EMA.
- European Medicines Agency. Qalsody (tofersen) – EPAR. EU authorisation 29.05.2024. EMA.
Editorial note: Literature search and source verification through 01 September 2026. This expert article is intended for scientific context. It does not replace medical diagnosis, an individual treatment decision or the product information for an authorised medicinal product or medical device.